Rachel Schneider, MD
Ophthalmology · Knoxville, TNNPI 1831540475
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,810 of the $12,058 with a category attached, or 64.8%. 25 manufacturers reported payments, led by Lensar, Inc. at 42.0% of the total. Reporting peaked in 2023 at $6,101 and has fallen 73.1% since, to $1,639 in 2025. Among ophthalmology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $66.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$5K
- Bausch & Lomb Americas Inc.$997
- Biotissue Holdings Inc.$911
- Mallinckrodt Hospital Products Inc.$871
- Alcon$613
- Sun Pharmaceutical Industries Inc.$414
- plus $3K from 19 others
What the payments were for
- Consulting fees$3,90032%
- Food & beverage$7,81065%
- Education$3483%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lensar, Inc. | 9 | $5,066 |
| Bausch & Lomb Americas Inc. | 20 | $997 |
| Biotissue Holdings Inc. | 14 | $911 |
| Mallinckrodt Hospital Products Inc. | 23 | $871 |
| Alcon | 17 | $613 |
| Sun Pharmaceutical Industries Inc. | 16 | $414 |
| Tarsus Pharmaceuticals, Inc. | 21 | $382 |
| Amgen(2 entities) | 8 | $368 |
| Carl Zeiss Meditec, Inc. | 5 | $353 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $321 |
| AbbVie | 8 | $270 |
| Beaver-visitec International, Inc. | 1 | $250 |
| Dompe US, Inc. | 6 | $242 |
| Glaukos Corporation | 3 | $228 |
| Rxsight Inc | 3 | $204 |
| Aerie Pharmaceuticals, Inc. | 5 | $160 |
| Sight Sciences, Inc. | 2 | $111 |
| Oyster Point Pharma, Inc. | 3 | $68 |
| Johnson & Johnson | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Harrow Eye, LLC | 2 | $37 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Carl Zeiss Meditec USA, Inc. | 1 | $21 |
| Thea Pharma Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$4,974
- enVista MX60 IOL$412
- AcrySof IQ PanOptix$272
- TEPEZZA$231
- ACTHAR$226
- AcrySof IQ VIVITY IOL$150
- enVista Aspire IOL$150
- iDoseTR$147
- ARTEVO 800$146
- IOLMaster 700$146
- VERACITY SURGICAL$146
- QUATERA 700$146
- Tecnis Simplicity$126
- DURYSTA$125
- Prokera$124
- AmnioGraft$124
- Oxervate$120
- STELLARIS ELITE$112
- Crystalens Accommodating IOL (AT-52AO)$112
- Trulign IOL$112
How this compares
$12,058 in reported general payments places this provider in the 90th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 67 | $79,660 |
| MieboPerfluorohexyloctane/Pf | 25 | $18,911 |
| RhopressaNetarsudil Mesylate | 24 | $12,032 |
| LumiganBimatoprost | 16 | $11,177 |
| Prednisolone Acetate | 228 | $10,630 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $10,623 |
| CequaCyclosporine | 12 | $10,125 |
| TyrvayaVarenicline Tartrate | 11 | $9,481 |
| Loteprednol Etabonate | 29 | $5,920 |
| Cyclosporine | 11 | $5,135 |
| Ketorolac Tromethamine | 179 | $3,530 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,380 |
| Difluprednate | 29 | $2,749 |
| MoxifloxacinMoxifloxacin Hcl | 67 | $1,695 |
| Brimonidine Tartrate | 158 | $1,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $270 | $90,83783 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $160 | $22,65546 claims |
| Bausch & Lomb Americas Inc.Miebo | $997 | $18,91125 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $414 | $10,12512 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $68 | $9,48111 claims |
| AlconSimbrinza | $613 | $3,38015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Knoxville
- Matthew ColeKnoxville$8K
- Darin SmithKnoxville$5K
- Deborah ShermanNashville$3M
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian BiesmanNashville$630K
- Brian FowlerMemphis$206K
- Edward ChaumNashville$158K
- Brian JerkinsMemphis$150K
- James FreemanMemphis$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.